Delaware
|
33-0728374
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
incorporation)
|
Identification No.)
|
On February 23, 2011, Dynavax issued a press release titled "Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue to Study Completion." A copy of the press release is attached as Exhibit 99.3 to this current report and is incorporated herein by reference.
Dynavax Technologies Corporation
|
||||||||
Date: February 24, 2011
|
By:
|
/s/ Michael S. Ostrach
|
||||||
Michael S. Ostrach
|
||||||||
Vice President
|
||||||||
Exhibit No.
|
Description
|
|
EX-99.1
|
Press Release, dated February 22, 2011, titled "Dynavax Reports New Phase 1a and Phase 1b Data for Universal Flu Vaccine Candidate."
|
|
EX-99.2
|
Press Release, dated February 22, 2011, titled "Dynavax Reports Additional Positive Phase 1B Immunogenicity Data for Hepatitis B Therapy Candidate."
|
|
EX-99.3
|
Press Release, dated February 23, 2011, titled "Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue to Study Completion."
|